Vaxart Inc
VXRT
$0.84
Closing
▼-2.75%
1D
▲47.05%
YTD
Market cap
$146.44M
52 week high
$1.59
52 week low
$0.54
Volume
128,054
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$146.44M
Analysts' Rating
BUY
Price Target (Mean)
4.5
Total Analysts
3
P/E
Operating Margin
-848.26%
Beta
0.70
Revenue Growth (Annual)
-88.00%
52 week high
$1.59
52 week low
$0.54
Div. Yield
%
EPS Annual Growth
-31.25
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its programs include tablet vaccine candidates designed to protect against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine candidate for human papillomavirus (HPV). The Company’s product pipeline includes norovirus vaccine, an oral tablet vaccine candidate that protect against norovirus GI and norovirus GII, by targeting the norovirus GI.1 Norwalk strain and the norovirus GII.4 Sydney strain; influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. The Company is also developing therapeutic vaccines for cervical cancer.
